Activating RAS missense mutations are among the most prevalent genomic alterations
observed in human cancers and drive oncogenesis in the three most lethal tumor types …

Intracellular oncoproteins can be inhibited with targeted therapy, but responses are not
durable. Immune therapies can be curative, but most oncogene-driven tumors are …

Chimeric antigen receptor (CAR) T cells have emerged as a promising class of therapeutic
agents, generating remarkable responses in the clinic for a subset of human cancers. One …

Background Tumor-specific mutated proteins can create immunogenic non-self, mutation-
containing 'neoepitopes' that are attractive targets for adoptive T-cell therapies. To avoid the …

Bacteriophage-eukaryotic cell interaction provides the biological foundation of Phage
Display technology, which has been widely adopted in studies involving protein-protein and …

CD3 bispecific T-cell engagers (TCE), comprised of a tumor-targeting domain linked to a
CD3 binding domain, function by bridging target-positive tumors and CD3-expressing …